Drostanolone propionate is an injectable anabolic/androgenic steroid (AAS). It is highly androgenic and mildly anabolic. Drostanolone does not aromatize into estrogens and has similar properties to dihydrotestosterone (DHT).
Drostanolone originally was developed to be used as an anti-estrogenic compound for treating female breast cancer. Drostanolone is irreversibly metabolized by the enzyme 3a-hydroxysteroid-dehydrogenase into an inactive form of 2α-methyl-5α-androstan-3α-ol-17-one.
Dosage and administration
Effective adult dose (male): up to 150mg per day by intramuscular injection
Effective adult dose (female): 100-400mg per week by intramuscular injection
Contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.
Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma.